Lundbeck turns in promising depression data

Lundbeck and its development partner Takeda have announced positive Phase II results for Lu AA21004, a treatment for depression. Study data showed significant improvements on the primary efficacy endpoints with both 5 and 10 mg compared to placebo. Lundbeck and Takeda will plan the next steps for Lu A21004 development after the Phase II data has been fully analyzed.

This Phase II data is a much-needed dose of good news for the company. Lundbeck recently suffered a setback with the failure of its sleep aid gaboxadol and stroke drug Desmoteplase. The Denmark-based developer still needs to acquire additional drug candidates to boost its business.

- see the release

Related Articles:
Lundbeck chair exits as company seeks calm. Report
Lundbeck looking to fill gap left by gaboxadol. Report
Lundbeck's shares plunge as drug flunks Phase III. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.